A therapeutic platform is a common base of technologies leveraged to produce multiple novel therapeutics with reduced asset-specific add-on technologies. These platforms offer synergy, add flexibility to develop an asset for any indication and enable faster scaling.


Given the therapeutic platform model’s potential to help pharma companies navigate key risks and challenges, we set out to explore its promises, its unique value drivers and why large pharma should embrace it. We analyzed all in-house development, collaborations, licensing deals and acquisitions related to a therapeutic platform for 2012-2022 to identify the exposure of the 18 largest pharmaceutical companies to platforms.


Download this white paper to learn:

  • How much large pharma is investing in therapeutic platforms
  • Trends in cell and gene therapy platform investments
  • Where therapeutic platforms deliver cost synergies
  • Which companies are the early movers and late movers in platform capabilities